Peter A. Bealjoins ProQR’s scientific advisory board, bringing with him tremendous experience in the field of RNA-based therapeutics, particularly in the area of RNA editing.
- As an expert in the field of ADAR and A-to-I editing, Dr. Beal will be instrumental in advancing the company’s novel and proprietary Axiomer® RNA editing technology.
- The board now consists of seven members: Dr.
Peter Beal, Dr. Art Levin, Dr. Thaddeus (Ted) Dryja, Dr. Phil Zamore, Dr. Cy Stein, Dr. Scott Armstrongand Dr. Annemieke Aartsma-Rus, and is chaired by Gerard Platenburg, Chief Innovation Officer of ProQR.
“The field of RNA editing with ADAR is exciting and holds the potential to generate a whole new class of therapeutics,” said Dr.
Dr. Beal is an influential leader in the field of RNA editing and Professor in the department of chemistry at UC Davis. His research focuses on the use of chemical approaches to the study of RNA biology with a particular emphasis on RNA editing and RNA interference. Dr. Beal received a Bachelor of Science degree from
ProQR and Dr. Beal have been collaborating extensively on the optimization of ProQR’s proprietary Axiomer® A-to-I editing technology. By the administration of just a single stranded editing oligonucleotide (or EON), the Axiomer® technology enables the recruitment of endogenous ADAR (adenosine deaminases acting on RNA) to edit individual nucleotides in the RNA, without the need for bacterial enzymes or viral vectors. The technology platform enables a patient’s body to repair its own RNA specifically and reversibly and could be applicable to over 20,000 disease-causing mutations.
“Given Dr. Beal’s exceptional background in RNA research, we are very pleased to welcome Peter to our scientific advisory board,” said
The other members of the SAB are:
Art Levin Ph.D., has more than two decades of experience in RNA drug development from discovery through drug registration, both in large pharma and biotech companies. He has been key to the development of numerous oligonucleotides, including the first-approved antisense medicines, and the first microRNA-targeted therapeutic in clinical trials. He is currently the Executive Vice President, Research and Development at Avidity Biosciences and Dr. Levin has published over 60 scientific articles and served as a director of the
Phil Zamore Ph.D., is a Howard Hughes Medical Institute Investigator, Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the
Cy Stein Ph.D., M.D., is a Professor of Medical Oncology and Molecular and Cellular Biology and the former chair of the
Annemieke Aartsma-Rus Ph.D., professor of Translational Genetics at the
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding our SAB members, and statements regarding our product candidates, including our development and their therapeutic potential. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the
Chief Financial Officer
T: +1 415 231 6431
Source: ProQR Therapeutics N.V.